ALBANY, N.Y., March 16, 2023 (GLOBE NEWSWIRE) -- Curia, a leading contract research, development and manufacturing organization, today announced that Philip Macnabb has been appointed as chief executive officer, succeeding John Ratliff.

See more here:
Curia Appoints Philip Macnabb as Chief Executive Officer

Basel, March 16, 2023 — Novartis today announced the U.S. Food and Drug Administration (FDA) granted approval for Tafinlar® (dabrafenib) + Mekinist® (trametinib) for the treatment of pediatric patients 1 year of age and older with low-grade glioma (LGG) with a BRAF V600E mutation who require systemic therapy. The FDA also approved liquid formulations of Tafinlar and Mekinist, marking the first time a BRAF/MEK inhibitor has been developed in a formulation suitable for patients as young as one year of age. These approvals make Tafinlar + Mekinist the first and only approved combination targeted therapy to treat pediatric patients with BRAF V600E LGG.

Link:
Novartis Tafinlar + Mekinist approved by FDA for pediatric patients with BRAF V600E low-grade glioma, the most common pediatric brain cancer

JASPER THERAPEUTICS, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K)  Marketscreener.com

See the original post:
JASPER THERAPEUTICS, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K) - Marketscreener.com

For a range of unmet medical needs, India offers a fantastic opportunity to push cell and gene therapies: B ..  ETHealthWorld

Link:
For a range of unmet medical needs, India offers a fantastic opportunity to push cell and gene therapies: B .. - ETHealthWorld

SAN FRANCISCO, March 08, 2023 (GLOBE NEWSWIRE) -- Neurona Therapeutics, a clinical-stage biotherapeutics company advancing regenerative cell therapies for the treatment of neurological disorders, announced that Cory R. Nicholas, Ph.D., Neurona’s chief executive officer, will provide a corporate update at the Oppenheimer 33rd Annual Healthcare Conference on Wednesday, March 15 at 2:00 pm ET.

Original post:
Neurona Therapeutics Announces Presentation at the Oppenheimer 33rd Annual Healthcare Conference

CHARLOTTESVILLE, Va. and CARMEL, Ind., March 08, 2023 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer’s disease, announced today that management will participate in a fireside chat at the Needham Virtual Neuroscience Forum on Wednesday, March 15, 2023 at 10:00 a.m. ET. The live webcast may be accessed under the Investors tab on www.acumenpharm.com and will be archived for 14 days.

Follow this link:
Acumen Pharmaceuticals to Participate in the Needham Neuroscience Forum

Company to participate in Type C meeting for IV Tramadol with FDA on March 9, 2023 Company to participate in Type C meeting for IV Tramadol with FDA on March 9, 2023

Continue reading here:
Avenue Therapeutics Provides Regulatory Update on IV Tramadol and Other Corporate Updates

SAN DIEGO, March 08, 2023 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development platform to advance its pipeline of novel targeted cancer therapeutics and to partner with other life science companies, today announced financial results for the fourth quarter and year ended December 31, 2022. The Company will host a conference call and webcast today at 4:30 PM Eastern Time / 1:30 PM Pacific Time.

Read more here:
TRACON Pharmaceuticals Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Corporate Update

SAN DIEGO, March 08, 2023 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide, today announced that Mark Rothera, its President and Chief Executive Officer, and Lisa Rojkjaer, M.D., its Chief Medical Officer, are scheduled to participate in a virtual fireside chat at the 33rd Annual Oppenheimer Healthcare Conference on Wednesday, March 15, 2023, at 12:00 p.m. ET.

Excerpt from:
Viracta Therapeutics to Present at the 33rd Annual Oppenheimer Healthcare Conference

ROCKVILLE, Md., March 08, 2023 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that the Supernus Pharmaceuticals management team will participate in the following March investor conferences:

Visit link:
Supernus to Participate in Two Upcoming Investor Conferences

SAN FRANCISCO, March 08, 2023 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Phil Pang, M.D., Ph.D., Executive Vice President, Chief Medical Officer and Interim Head of Research, is scheduled to present at the Barclays Global Healthcare Conference on Wednesday, March 15, at 7:15 a.m. PT / 10:15 a.m. ET.

Link:
Vir Biotechnology to Participate in the Barclays Global Healthcare Conference

Conference call to begin at 4:30 p.m. ET

Originally posted here:
Vaxart to Host Full Year 2022 Business Update and Financial Results Conference Call on March 15

REDWOOD CITY, Calif., March 08, 2023 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address diseases such as chronic spontaneous urticaria, lower to intermediate risk myelodysplastic syndromes (MDS) as well as novel stem cell transplant conditioning regimes, today announced results for the fiscal year ended December 31, 2022, and provided a business update.

See the article here:
Jasper Therapeutics Reports Fiscal 2022 Financial Results and Provides a Business Update

Webcast set for 7:30 a.m. ET on March 9 Webcast set for 7:30 a.m. ET on March 9

Original post:
Clene to Announce New CNM-Au8® Data From the Healey ALS Platform Trial

Full-Year Net Revenue of $10 Million and Fourth Quarter Net Revenue of $2.6 Million

Continued here:
Nephros Announces Fourth Quarter and Fiscal Year 2022 Financial Results

NEW YORK, March 08, 2023 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today provided a business update and announced its results for the fourth quarter of 2022, and full year ending December 31, 2022.

See the original post:
Cellectis Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results

NEWS RELEASE – REGULATED INFORMATIONMARCH 8, 2023, 5:00 pm ET/ 23:00 CET

Read more here:
MDxHealth Announces Update of Outstanding Shares and Voting Rights

TORONTO and CHICAGO, March 08, 2023 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals (TSX: MDP; TSX: MDP.DB; OTCQX: MEDXF) today entered into a new senior secured credit agreement agented by BMO. The credit agreement provides for a US$35 million term loan facility and a US$3.5 million revolving loan facility for working capital. The term loan facility benefits from an additional US$20 million uncommitted accordion feature, which Medexus is confident will be available. The new BMO facilities will mature in March 2026, being three years from the date of the credit agreement.

More:
Medexus Announces US$58.5 million in New Credit Facilities

SEATTLE, March 08, 2023 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced that it has engaged SVB Securities to assist in reviewing strategic alternatives for the Company with the goal of maximizing shareholder value. Such alternatives may include a sale, merger, divestiture of assets, licensing or other strategic transaction. There can be no assurance that the exploration of strategic alternatives will result in any agreements or transactions, or that, if completed, any agreements or transactions will be successful or on attractive terms. Neoleukin does not expect to disclose or provide an update concerning developments related to this process until the Company enters into definitive agreements or arrangements with respect to a transaction or otherwise determines that other disclosure is necessary or appropriate.

Follow this link:
Neoleukin Therapeutics Provides Strategic Update and Announces Restructuring and Leadership Transition

– Nirogacestat Treatment Significantly Improved Progression-Free Survival, Objective Response Rate and Key Patient Reported Outcomes –

View original post here:
SpringWorks Therapeutics Announces New England Journal of Medicine Publication of Phase 3 DeFi Trial Evaluating Nirogacestat in Adults with Desmoid...